Nature Communications (Oct 2020)
Immunological fingerprint of 4CMenB recombinant antigens via protein microarray reveals key immunosignatures correlating with bactericidal activity
- E. Bartolini,
- E. Borgogni,
- M. Bruttini,
- A. Muzzi,
- M. Giuliani,
- S. Iozzi,
- R. Petracca,
- M. Martinelli,
- S. Bonacci,
- S. Marchi,
- C. Brettoni,
- C. Donati,
- G. Torricelli,
- S. Guidotti,
- M. Domina,
- C. Beninati,
- G. Teti,
- F. Felici,
- R. Rappuoli,
- F. Castellino,
- G. Del Giudice,
- V. Masignani,
- M. Pizza,
- D. Maione
Affiliations
- E. Bartolini
- GSK
- E. Borgogni
- GSK
- M. Bruttini
- GSK
- A. Muzzi
- GSK
- M. Giuliani
- GSK
- S. Iozzi
- GSK
- R. Petracca
- GSK
- M. Martinelli
- GSK
- S. Bonacci
- GSK
- S. Marchi
- GSK
- C. Brettoni
- GSK
- C. Donati
- GSK
- G. Torricelli
- GSK
- S. Guidotti
- GSK
- M. Domina
- University of Messina
- C. Beninati
- University of Messina
- G. Teti
- University of Messina
- F. Felici
- University of Molise
- R. Rappuoli
- GSK
- F. Castellino
- GSK
- G. Del Giudice
- GSK
- V. Masignani
- GSK
- M. Pizza
- GSK
- D. Maione
- GSK
- DOI
- https://doi.org/10.1038/s41467-020-18791-0
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 12
Abstract
4CMenB is an approved multi-component vaccine against Serogroup B meningococcus. Here the authors develop a protein microarray for three major 4CMenB antigenic components (fHbp, NHBA and NadA) and describe antibody repertoires in sera from vaccinated infants, adolescents and adults correlating with bactericidal response.
